Pharvaris to Present at SVB Securities Global Biopharma Conference

Rhea-AI Summary

Pharvaris (Nasdaq: PHVS), a clinical-stage company, is focused on developing oral bradykinin-B2-receptor antagonists for treating and preventing hereditary angioedema (HAE) attacks. The company announced its participation in the SVB Securities Global Biopharma Conference, scheduled virtually from February 14–16, 2023. Pharvaris will present on February 15, at 2:40 p.m. CEST (8:40 a.m. EST), with a live audio webcast accessible on their Investor page. A replay will be available for 30 days post-presentation. Pharvaris aims to provide safe and effective treatment options for all HAE sub-types, leveraging its specialized knowledge in rare diseases.

ZUG, Switzerland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that management will present at the SVB Securities Global Biopharma Conference taking place virtually from February 14–16, 2023.

Pharvaris’ presentation will take place on Wednesday, February 15, at 2:40 p.m. CEST (8:40 a.m. EST). A live audio webcast will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. A replay will be available on Pharvaris’ website for 30 days following the presentation.

About Pharvaris
Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in HAE. By directly targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE safe, effective, and convenient alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.

Contact
Maryann Cimino
Director of Corporate Relations
maryann.cimino@pharvaris.com 
+1-617-710-7305

FAQ

What is Pharvaris presenting at the SVB Securities Global Biopharma Conference?

Pharvaris is presenting on February 15, 2023, at the SVB Securities Global Biopharma Conference.

When is the SVB Securities Global Biopharma Conference taking place?

The SVB Securities Global Biopharma Conference occurs from February 14 to February 16, 2023.

What time is Pharvaris' presentation scheduled for?

Pharvaris' presentation is scheduled for February 15, 2023, at 2:40 p.m. CEST (8:40 a.m. EST).

How can I access Pharvaris' presentation?

Pharvaris' presentation will be available via a live audio webcast on their Investor page.

Will there be a replay of Pharvaris' presentation?

Yes, a replay of Pharvaris' presentation will be available on their website for 30 days following the event.